|
1
|
Ströbel P, Marx A, Zettl A and
Müller-Hermelink HK: Thymoma and thymic carcinoma: an update of the
WHO Classification 2004. Surg Today. 35:805–811. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Engels EA: Epidemiology of thymoma and
associated malignancies. J Thorac Oncol. 5(Suppl 4): S260–S265.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed. Proceedings of the
First International Conference on Thymic Malignancies; August
20–21, 2009; Bethesda, Maryland, USA. J Thorac Oncol. 5(Suppl 4):
pp. S259–S370. 2010
|
|
4
|
Kondo K and Monden Y: Therapy for thymic
epithelial tumors: a clinical study of 1,320 patients from Japan.
Ann Thorac Surg. 76:878–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masaoka A, Yamakawa Y, Niwa H, et al:
Thymectomy and malignancy. Eur J Cardiothorac Surg. 8:251–253.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ströbel P, Bauer A, Puppe B, et al: Tumor
recurrence and survival in patients treated for thymomas and thymic
squamous cell carcinomas: a retrospective analysis. J Clin Oncol.
22:1501–1509. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Girard N, Mornex F, Van Houtte P, Cordier
JF and van Schil P: Thymoma: a focus on current therapeutic
management. J Thorac Oncol. 4:119–126. 2009. View Article : Google Scholar
|
|
8
|
Rashid OM, Cassano AD and Takabe K: Thymic
neoplasm: a rare disease with a complex clinical presentation. J
Thorac Dis. 5:173–183. 2013.PubMed/NCBI
|
|
9
|
NCCN Guidelines on the Treatment of
Thymomas and Thymic Carsinomas. http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf.
Accessed May 18, 2014
|
|
10
|
Lemma GL, Lee JW, Aisner SC, et al: Phase
II study of carboplatin and paclitaxel in advanced thymoma and
thymic carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan CC, Chen PC and Chiang H: KIT (CD117)
is frequently overexpressed in thymic carcinomas but is absent in
thymomas. J Pathol. 202:375–381. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki M, Chen H, Shigematsu H, et al:
Aberrant methylation: common in thymic carcinomas, rare in
thymomas. Oncol Rep. 14:1621–1624. 2005.PubMed/NCBI
|
|
13
|
Girard N, Shen R, Guo T, et al:
Comprehensive genomic analysis reveals clinically relevant
molecular distinctions between thymic carcinomas and thymomas. Clin
Cancer Res. 15:6790–6799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoh K, Nishiwaki Y, Ishii G, et al:
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Lung Cancer. 62:316–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ströbel P, Bargou R, Wolff A, et al:
Sunitinib in metastatic thymic carcinomas: laboratory findings and
initial clinical experience. Br J Cancer. 103:196–200. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schirosi L, Nannini N, Nicoli D, et al:
Activating c-KIT mutations in a subset of thymic carcinoma and
response to different c-KIT inhibitors. Ann Oncol. 23:2409–2414.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bisagni G, Rossi G, Cavazza A, et al: Long
lasting response to the multikinase inhibitor bay 43–9006
(Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J
Thorac Oncol. 4:773–775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li XF, Chen Q, Huang WX and Ye YB:
Response to sorafenib in cisplatin-resistant thymic carcinoma: a
case report. Med Oncol. 26:157–160. 2009. View Article : Google Scholar
|
|
19
|
Gardner ER, Dahut WL, Scripture CD, et al:
Randomized crossover pharmacokinetic study of solvent-based
paclitaxel and nab-paclitaxel. Clin Cancer Res. 14:4200–4205. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Socinski MA, Langer CJ, Okamoto I, et al:
Safety and efficacy of weekly nab®-paclitaxel in combination with
carboplatin as first-line therapy in elderly patients with advanced
non-small-cell lung cancer. Ann Oncol. 24:314–321. 2013. View Article : Google Scholar
|
|
21
|
Socinski MA, Bondarenko I, Karaseva NA, et
al: Weekly nab-paclitaxel in combination with carboplatin versus
solvent-based paclitaxel plus carboplatin as first-line therapy in
patients with advanced non-small-cell lung cancer: final results of
a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
